Research progress in tumor targeted immunotherapy

Expert Opin Drug Deliv. 2021 Aug;18(8):1067-1090. doi: 10.1080/17425247.2021.1882992. Epub 2021 Apr 14.

Abstract

Introduction: Compared with traditional cancer treatment methods, tumor-targeted immunotherapy can combine targeted therapy and immunotherapy with long-lasting responses to achieve synergistic therapy, which brings hope to the complete cure of cancer.

Areas covered: This review summarizes the newest and most up-to-date advances in tumor-targeted immunotherapy, including tumor-associated macrophages (TAMs) targeted immunotherapy, regulatory T (Treg) cells targeted immunotherapy, tumor-associated fibroblasts (TAFs) targeted immunotherapy and immune checkpoints targeted immunotherapy.

Expert opinion: Immunotherapy can restore anti-tumor immunity in the tumor microenvironment and produce a lasting immune surveillance effect. Smart multifunctional nano delivery system can effectively combine targeted therapy with immunotherapy, which has attracted extensive attention. With the deepening of research, more and more tumor-targeted immunotherapy enter into the clinical trial phases, especially antibodies and inhibitors. Tumor-targeted immunotherapy is a promising approach for conquering cancer and bringing hope for human health.

Keywords: Cancer immunotherapy; Treg cells; immune checkpoints; nanoparticles; targeted therapy; tumor-associated fibroblasts; tumor-associated macrophages.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Immunotherapy*
  • Neoplasms* / therapy
  • Tumor Microenvironment